Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Primary Progressive Multiple Sclerosis (PPMS) Clear all

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Tolebrutinib, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 45
States / cities: La Jolla, California • Los Alamitos, California • Los Angeles, California + 41 more

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Placebo, Laquinimod; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 15
States / cities: Phoenix, Arizona • Newport Beach, California • San Francisco, California + 11 more

Conditions: B-cell Mediated Autoimmune Disorders
Interventions: Azercabtagene zapreleucel (azer-cel); Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Ocrelizumab; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 732 participants
Timeline: 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Primary Progressive Multiple Sclerosis
Interventions: DUOC-01; Biological
Lead sponsor: Joanne Kurtzberg, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Multiple Sclerosis
Interventions: Strategy-Based Training to Enhance Memory (STEM), Placebo control exercises; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 59 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: East Hanover, New Jersey • Marlton, New Jersey

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab, Antihistamine, Methylprednisolone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 24
States / cities: Homewood, Alabama • Phoenix, Arizona • Irvine, California + 21 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab Dose 1, Ocrelizumab Dose 2 and Dose 3; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Wellesley, Massachusetts • Cleveland, Ohio + 2 more

Conditions: Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Interventions: Ocrelizumab, Lumbar Puncture, Methyloprednisolone, Antihistamine; Drug · Procedure
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Ocrelizumab; Other
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Primary Progressive Multiple Sclerosis
Interventions: FTY720, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 33
States / cities: Newport Beach, California • Sacramento, California • Aurora, Colorado + 29 more

Conditions: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
Interventions: TRX319, Bendamustine; Biological · Drug
Lead sponsor: Tr1X, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Kansas City, Kansas • St Louis, Missouri

Conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
Interventions: IDP-023, Ocrelizumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna; Drug
Lead sponsor: Indapta Therapeutics, INC.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more

Search by objective public record fields.

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)

Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis